• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

    1/31/22 10:58:24 AM ET
    $AYLA
    Specialty Chemicals
    Consumer Discretionary
    Get the next $AYLA alert in real time by email
    SC 13G/A 1 zk2227147.htm SC 13G/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G/A
    (Amendment No. 1)*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND
    AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    Ayala Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.01 per share
    (Title of Class of Securities)
     
     
    05465V108
     
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

    Check the following box to designate the rule pursuant to which the Schedule is filed:

    ☐ Rule 13d-1(b)

    ⌧ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP NO. 05465V108

    1
    Name of Reporting Persons
     
     
    Harel Insurance Investments & Financial Services Ltd.
     
     
     
     
    2
    Check the Appropriate Box if a Member of a Group
       
    (a) ☒
       
    (b) ☐
     
     
    3
    SEC Use only
     
     
     
     
     
     
     
    4
    Place of Organization
     
     
    Israel
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    Sole Voting Power
     
     
    0
     
     
     
     
    6
    Shared Voting Power
     
     
    2,153,272 Shares*
     
     
     
     
    7
    Sole Dispositive Power
     
     
    0
     
     
     
     
    8
    Shared Dispositive Power
     
     
    2,153,272 Shares*
     
     
     
     
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     
    2,153,272 Shares*
     
     
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
     
    ☐
     
     
     
     
    11
    Percent of Class Represented by Amount in Row (9)
     
     
    15.5%**
     
     
     
     
    12
    Type of Reporting Person:
     
     
    CO
     
     
     
     

    *See Item 4.
    ** Based on 13,935,254 shares of Common Stock issued and outstanding as of November 1, 2021 (as reported by the Issuer in Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021).

    - 2 -

    CUSIP NO. 05465V108

    1
    Name of Reporting Persons
     
     
    Harel Insurance Company Ltd.
     
     
     
     
    2
    Check the Appropriate Box if a Member of a Group
       
    (a) ☒
       
    (b) ☐
     
     
    3
    SEC Use only
     
     
     
     
     
     
     
    4
    Place of Organization
     
     
    Israel
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    Sole Voting Power
     
     
    0
     
     
     
     
    6
    Shared Voting Power
     
     
    2,153,272 Shares*
     
     
     
     
    7
    Sole Dispositive Power
     
     
    0
     
     
     
     
    8
    Shared Dispositive Power
     
     
    2,153,272 Shares*
     
     
     
     
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     
    2,153,272 Shares*
     
     
     
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
     
    ☐
     
     
     
     
    11
    Percent of Class Represented by Amount in Row (9)
     
     
    15.5%**
     
     
     
     
    12
    Type of Reporting Person:
     
     
    CO
     
     
     
     

    *See Item 4.
    ** Based on 13,935,254 shares of Common Stock issued and outstanding as of November 1, 2021 (as reported by the Issuer in Report on Form 10-Q filed with the Securities and Exchange Commission on November 15, 2021).


    - 3 -


    Item 1.

    (a)
    Name of Issuer:

    Ayala Pharmaceuticals, Inc. (the “Issuer”).

    (b)
    Address of Issuer’s Principal Executive Offices:

    Oppenheimer 4, Rehovot 7670104, Israel.

    Item 2.

    (a)-(c)
    Name of Person Filing, address and citizenship:

    The following entities are referred to as the “Reporting Persons” in this Statement:

    Harel Insurance Investments & Financial Services Ltd. (“Harel Holdings”), an Israeli public company, with a principal business address at Harel House; 3 Aba Hillel Street; Ramat Gan 52118, Israel.

    Harel Insurance Company Ltd. (“Harel Insurance”), an Israeli company wholly owned by Harel Holdings, with a principal business address at Harel House; 3 Aba Hillel Street; Ramat Gan 52118, Israel.

    (d)
    Title of Class of Securities:

    Common Stock, par value $0.01 per share (the “Shares”).

    (e)
    CUSIP Number:


    05465V108

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

    Item 4.
    Ownership

    Of the 2,153,272 Shares reported in this Statement as beneficially owned by the Reporting Person (i) 489,438 Shares are held for members of the public through, among others, provident funds and/or mutual funds and/or pension funds and/or insurance policies and/or exchange traded funds, which are managed by subsidiaries of the Reporting Persons, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, and (ii) 1,663,834 Shares are beneficially held for Harel Insurance’s own account. Consequently, this Statement shall not be construed as an admission by the Reporting Persons that they are the beneficial owners of, or have any pecuniary interest for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, in, more than 1,663,834 Shares.

    Except as set forth above, see items 5-11 of the cover pages hereto for beneficial ownership, percentage of class and dispositive power of the Reporting Person, which are incorporated herein.

    Item 5.
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7.
    Identification and Classification of the Subsidiary, Which Acquired the Security Being Reported on by the Parent Holding Company

    Not Applicable.

    - 4 -

    Item 8.
    Identification and Classification of Members of the Group

    Not Applicable.

    Item 9.
    Notice of Dissolution of Group

    Not Applicable.

    Item 10.
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    - 5 -

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    January 31, 2022

     
    HAREL INSURANCE INVESTMENTS AND FINANCIAL SERVICES LTD.
       
     
    BY: /s/ Uri Rabinovitz
     
    Name, Title: Uri Rabinovitz, Vice President
     
     
    HAREL INSURANCE COMPANY LTD.
       
     
    BY: /s/ Uri Rabinovitz
     
    Name, Title: Uri Rabinovitz, Vice President

    - 6 -
    Get the next $AYLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AYLA

    DatePrice TargetRatingAnalyst
    12/20/2021$22.00Buy
    Maxim Group
    12/20/2021$18.00Buy
    HC Wainwright & Co.
    11/30/2021$12.00 → $17.00Hold → Buy
    Jefferies
    8/17/2021$27.00 → $25.00Outperform
    Oppenheimer
    7/13/2021$29.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $AYLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Advaxis and Ayala Pharmaceuticals Complete Merger

      REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX:ADXS), a biotechnology company devoted to the discovery, development and commercialization of immunotherapies based on a technology which uses engineered Listeria monocytogenes (Lm), today announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the na

      1/19/23 9:37:49 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Presents Poster on AL102 in Desmoid Tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting

      REHOVOT, Israel and WILMINGTON, Del., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today is announcing a poster presentation highlighting interim results from the Phase 2 segment / Part A of the RINGSIDE Pivotal Phase 2/3 clinical trial in desmoid tumors at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting, taking place in-person November 16-19 in Vancouver, Canada. The ongoing RINGSIDE Pivotal Phase 2/3 clinical trial is evaluating the investigational new drug AL102, a poten

      11/17/22 8:00:00 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Announces First Patient Dosed with AL102 in Phase 3 Segment of RINGSIDE Trial in Desmoid Tumors

      REHOVOT, Israel and WILMINGTON, Del., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers, today announced that the first patient has been dosed in Part B of RINGSIDE, the Phase 3 randomized segment of the trial evaluating AL102 in desmoid tumors. AL102 is a potent, selective, oral gamma-secretase inhibitor (GSI). "We are pleased to begin enrollment in the Phase 3 segment of RINGSIDE, which is a significant milestone in our AL102 development program," said Roni Mamluk, Ph.D., President and Chief Exec

      11/16/22 8:00:00 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Ayala Pharmaceuticals with a new price target

      Maxim Group initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      12/20/21 7:55:57 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • HC Wainwright & Co. initiated coverage on Ayala Pharmaceuticals with a new price target

      HC Wainwright & Co. initiated coverage of Ayala Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      12/20/21 6:22:04 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals upgraded by Jefferies with a new price target

      Jefferies upgraded Ayala Pharmaceuticals from Hold to Buy and set a new price target of $17.00 from $12.00 previously

      11/30/21 6:55:03 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    SEC Filings

    See more
    • SEC Form 10-K filed by Ayala Pharmaceuticals Inc.

      10-K - Old Ayala, Inc (0001797336) (Filer)

      3/31/23 6:38:48 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 15-12G filed by Ayala Pharmaceuticals Inc.

      15-12G - Old Ayala, Inc (0001797336) (Filer)

      1/30/23 3:30:02 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets

      8-K - Old Ayala, Inc (0001797336) (Filer)

      1/25/23 4:53:46 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AYLA
    Financials

    Live finance-specific insights

    See more
    • SEC Form 3 filed by new insider Martell Bridget A

      3 - Old Ayala, Inc (0001797336) (Issuer)

      11/1/23 4:04:06 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Orbach Pini

      3 - Old Ayala, Inc (0001797336) (Issuer)

      11/1/23 4:00:56 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form 3 filed by new insider Golan Roy

      3 - Old Ayala, Inc (0001797336) (Issuer)

      10/31/23 5:48:50 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressi

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary
    • Ayala Pharmaceuticals and Advaxis Enter into Merger Agreement

      Merger brings U.S. management and presence, cash to develop compelling late-stage asset Lead candidate AL102 being evaluated in ongoing Phase 2/3 RINGSIDE study, a potential registration trial in desmoid tumors Ayala and Advaxis stockholders will respectively own approximately 62.5% and 37.5% Combined Company to Seek Uplisting to Nasdaq Conference Call and Webcast today at 8:00am ET REHOVOT, Israel and WILMINGTON, Del. and MONMOUTH JUNCTION, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) --  Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) (Ayala), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggress

      10/19/22 6:30:00 AM ET
      $ADXS
      $AYLA
      Major Pharmaceuticals
      Health Care
      Specialty Chemicals
      Consumer Discretionary

    $AYLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Old Ayala, Inc (0001797336) (Subject)

      2/8/23 5:16:37 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G filed by Ayala Pharmaceuticals Inc.

      SC 13G - Old Ayala, Inc (0001797336) (Subject)

      2/7/23 6:01:50 AM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Ayala Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Old Ayala, Inc (0001797336) (Subject)

      2/6/23 2:49:38 PM ET
      $AYLA
      Specialty Chemicals
      Consumer Discretionary